Advanced in COVID-19

Dr. Emily A. Blumberg

Infectious Disease
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
On Staff At
Accepting New Patients
Offers Telehealth
40 Years of Experience
Advanced in COVID-19
3400 Civic Center Boulevard, South Pavilion, 4th Floor, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Emily Blumberg is an Infectious Disease provider in Philadelphia, Pennsylvania. Dr. Blumberg has been practicing medicine for over 40 years and is rated as an Advanced provider by MediFind in the treatment of COVID-19. Her top areas of expertise are Cytomegalovirus Infection, Cytomegalic Inclusion Disease, HIV/AIDS, and Hepatitis C. Dr. Blumberg is currently accepting new patients.

Her clinical research consists of co-authoring 167 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 15 articles and participated in 2 clinical trials in the study of COVID-19.

Graduate Institution
New York University
Residency
University of Chicago Medical Center
Specialties
Infectious Disease
Licenses
Internal Medicine in PA
Board Certifications
Internal Medicine, 1984
Fellowships
Albert Einstein - Montefiore Medical Center
Hospital Affiliations
Hospital Of Univ Of Pennsylvania
Languages Spoken
English
Gender
Female
Awards
Recognized annually in Philadelphia magazine's Top Docs issue from 2011 through 2025

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
Provider Partners Health Plan
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 18 Less Insurance Carriers -

Locations

MacGregor Infection Medicine and Travel Program
3400 Civic Center Boulevard, South Pavilion, 4th Floor, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Anti-Spike SARS-CoV-2 Monoclonal Antibodies as Pre-Exposure Prophylaxis to Prevent COVID-19 in Immunocompromised Participants
Enrollment Status: Terminated
Publish Date: October 17, 2025
Intervention Type: Drug
Study Drug: Casirivimab+Imdevimab
Study Phase: Phase 3
HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
HOPE in Action Prospective Multicenter, Clinical Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other
Study Phase: Not Applicable
A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
A Randomized Study to Evaluate Antibody Response to an Additional Dose of SARS-CoV-2 Vaccination With and Without Immunosuppression Reduction in Kidney and Liver Transplant Recipients
Enrollment Status: Completed
Publish Date: June 17, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Other
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
Phase I Trial for the Prevention of Cytokine Release Syndrome (CRS) With Cyclosporine in Patients With Moderate COVID-19
Enrollment Status: Completed
Publish Date: January 11, 2022
Intervention Type: Drug
Study Drug: Cyclosporine
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant
Enrollment Status: Completed
Publish Date: February 02, 2021
Intervention Type: Drug
Study Phase: Phase 4
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
Enrollment Status: Completed
Publish Date: November 01, 2019
View 8 Less Clinical Trials

167 Total Publications

APOL1 Genotype and Patient Outcomes in US and South African Transplant Recipients With HIV who Received Kidneys From Donors With HIV.
APOL1 Genotype and Patient Outcomes in US and South African Transplant Recipients With HIV who Received Kidneys From Donors With HIV.
Journal: Transplantation
Published: November 17, 2025
Similar Doctors
Distinguished in COVID-19
Dr. Theodore Markou
Infectious Disease
Distinguished in COVID-19
Dr. Theodore Markou
Infectious Disease

ID Care, PA

105 Raider Boulevard, Suite 101, 
Hillsborough, NJ 
 (47.3 miles away)
Languages Spoken:
English
See accepted insurances

Theodore Markou is an Infectious Disease provider in Hillsborough, New Jersey. Dr. Markou is rated as a Distinguished provider by MediFind in the treatment of COVID-19. His top areas of expertise are Sepsis, Pneumonia, COVID-19, and Multisystem Inflammatory Syndrome in Children (MIS-C).

Distinguished in COVID-19
Dr. Jonathan B. Cohen
Infectious Disease
Distinguished in COVID-19
Dr. Jonathan B. Cohen
Infectious Disease

St Lukes Physician Group Inc

3000 St Lukes Dr, 
Quakertown, PA 
 (35.7 miles away)
484-526-3950
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Cohen is an Infectious Disease provider in Quakertown, Pennsylvania. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of COVID-19. His top areas of expertise are COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), Severe Acute Respiratory Syndrome (SARS), Endoscopy, and Colonoscopy.

Distinguished in COVID-19
Dr. Thomas E. Michaelson
Infectious Disease
Distinguished in COVID-19
Dr. Thomas E. Michaelson
Infectious Disease

Infectious Diseases Associates PC

729 Grove Ave, Unit 4, 
Southampton, PA 
 (17.6 miles away)
215-355-9634
Languages Spoken:
English
See accepted insurances

Thomas Michaelson is an Infectious Disease provider in Southampton, Pennsylvania. Dr. Michaelson is rated as a Distinguished provider by MediFind in the treatment of COVID-19. His top areas of expertise are COVID-19, Osteomyelitis, Hospital-Acquired Pneumonia, and Pneumonia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Blumberg's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 22 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile